CU20210098A7 - Derivados de quinazolin-4-one útiles para el tratamiento de enfermedades y trastornos asociados con braf - Google Patents

Derivados de quinazolin-4-one útiles para el tratamiento de enfermedades y trastornos asociados con braf

Info

Publication number
CU20210098A7
CU20210098A7 CU2021000098A CU20210098A CU20210098A7 CU 20210098 A7 CU20210098 A7 CU 20210098A7 CU 2021000098 A CU2021000098 A CU 2021000098A CU 20210098 A CU20210098 A CU 20210098A CU 20210098 A7 CU20210098 A7 CU 20210098A7
Authority
CU
Cuba
Prior art keywords
braf
quinazolin
treatment
diseases
disorders associated
Prior art date
Application number
CU2021000098A
Other languages
English (en)
Inventor
Patrick Michael Barbour
Katie Keaton Brown
Adam Wade Cook
Erik James Hicken
Dean Russell Kahn
Ellen Ruth Laird
Andrew Terrance Metcalf
David Austin Moreno
Bradley Jon Newhouse
Spencer Phillip Pajk
Brett Joseph Prigaro
Li Ren
Eugene Tarlton
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CU20210098A7 publication Critical patent/CU20210098A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>En la presente invención se proporcionan derivados de quinazolin-4-ona de Fórmula I:</p> <p> </p> <p>ESPACIO PARA FÓRMULA</p> <p> </p> <p>en donde L, X1, R1, R2, R3, R4, R5 y R6 son como se definen aquí, para el tratamiento de enfermedades y trastornos asociados con BRAF, incluidos los tumores asociados con BRAF, incluidos los tumores malignos y benignos asociados con BRAF del SNC y tumores malignos extracraneales asociados a BRAF.</p>
CU2021000098A 2019-06-28 2020-06-24 Derivados de quinazolin-4-one útiles para el tratamiento de enfermedades y trastornos asociados con braf CU20210098A7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962868581P 2019-06-28 2019-06-28
US202063021410P 2020-05-07 2020-05-07
PCT/IB2020/055992 WO2020261156A1 (en) 2019-06-28 2020-06-24 Quinazolin-4-one derivatives useful for the treatment of braf-associated diseases and disorders

Publications (1)

Publication Number Publication Date
CU20210098A7 true CU20210098A7 (es) 2022-06-06

Family

ID=71465389

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2021000098A CU20210098A7 (es) 2019-06-28 2020-06-24 Derivados de quinazolin-4-one útiles para el tratamiento de enfermedades y trastornos asociados con braf

Country Status (20)

Country Link
US (2) US11414404B2 (es)
EP (1) EP3990437A1 (es)
JP (1) JP7169469B2 (es)
KR (1) KR20220011712A (es)
CN (1) CN114026073A (es)
AU (1) AU2020302352B2 (es)
BR (1) BR112021025102A2 (es)
CA (1) CA3144859C (es)
CO (1) CO2021017438A2 (es)
CR (1) CR20210626A (es)
CU (1) CU20210098A7 (es)
EC (1) ECSP21093541A (es)
IL (1) IL288214A (es)
MA (1) MA56387A (es)
MX (1) MX2021015903A (es)
PE (1) PE20220341A1 (es)
TW (1) TWI817018B (es)
UY (1) UY38767A (es)
WO (1) WO2020261156A1 (es)
ZA (1) ZA202201329B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
EP4073044A1 (en) * 2019-12-10 2022-10-19 F. Hoffmann-La Roche AG New braf inhibitors as paradox breakers
CR20220251A (es) * 2019-12-10 2022-07-11 Hoffmann La Roche Nuevos derivados de metilquinazolinona
MX2022015703A (es) 2020-06-09 2023-01-24 Array Biopharma Inc Compuestos para el tratamiento de enfermedades y trastornos asociados a braf.
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
KR20240005899A (ko) * 2021-06-09 2024-01-12 에프. 호프만-라 로슈 아게 암 치료를 위한 병용요법
CN118201615A (zh) * 2021-11-04 2024-06-14 豪夫迈·罗氏有限公司 喹唑啉酮化合物用于治疗癌症的新用途
AU2022403854A1 (en) * 2021-12-08 2024-05-23 Array Biopharma Inc. Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
WO2024105144A1 (en) * 2022-11-18 2024-05-23 F. Hoffmann-La Roche Ag Quinazolinone compound as braf inhibitor for the treatment of advanced solid cancer or metastases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE025767T2 (en) 2002-03-13 2016-05-30 Array Biopharma Inc N3-alkylated benzimidazole derivatives as MEK inhibitors
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
AU2004293019B2 (en) 2003-11-19 2010-10-28 Array Biopharma Inc. Bicyclic inhibitors of MEK and methods of use thereof
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
WO2006024834A1 (en) 2004-08-31 2006-03-09 Astrazeneca Ab Quinazolinone derivatives and their use as b-raf inhibitors
ES2405785T3 (es) 2005-05-18 2013-06-03 Array Biopharma Inc. Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
EP2007736A1 (en) 2006-04-05 2008-12-31 AstraZeneca AB Substituted quinazolines with anti-cancer activity
US20090170849A1 (en) 2006-04-05 2009-07-02 Astrazeneca Ab Quinazolinone derivatives having b-raf inhibitory activity
JP2009534364A (ja) * 2006-04-18 2009-09-24 アストラゼネカ アクチボラグ キナゾリン−４−オン誘導体、それらの製造方法およびそれらを含有する医薬組成物
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
EP2776037B1 (en) 2011-11-11 2019-01-09 Novartis AG Method of treating a proliferative disease
CN105899493B (zh) 2014-01-17 2019-03-29 诺华股份有限公司 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
ES2699351T3 (es) 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
CA3008312A1 (en) 2016-01-06 2017-07-13 Trillium Therapeutics Inc. Novel fluorinated quinazoline derivatives as egfr inhibitors
EP3878850A1 (en) 2016-12-22 2021-09-15 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
JP7394768B2 (ja) * 2017-09-20 2023-12-08 エイビーエム セラピューティックス コーポレイション キナーゼ阻害剤としての環状イミノピリミジン誘導体
EP3694848A1 (en) 2017-10-12 2020-08-19 Revolution Medicines, Inc. Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
WO2019071351A1 (en) 2017-10-12 2019-04-18 Trillium Therapeutics Inc. NOVEL 4-ARYLOXYQUINAZOLINE FLUORIN DERIVATIVES AS EGFR INHIBITORS USEFUL FOR THE TREATMENT OF CANCERS
UY38349A (es) 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
CN113711012A (zh) 2018-09-14 2021-11-26 联合利华知识产权控股有限公司 免洗型化妆品组合物保护皮肤免受污染的功效的评估
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物

Also Published As

Publication number Publication date
CA3144859C (en) 2023-09-12
MX2021015903A (es) 2022-02-03
BR112021025102A2 (pt) 2022-01-25
US20220289721A1 (en) 2022-09-15
CR20210626A (es) 2022-02-08
CO2021017438A2 (es) 2022-01-17
UY38767A (es) 2021-01-29
PE20220341A1 (es) 2022-03-14
JP2022539056A (ja) 2022-09-07
CA3144859A1 (en) 2020-12-30
US11634409B2 (en) 2023-04-25
US20200407344A1 (en) 2020-12-31
ZA202201329B (en) 2023-09-27
WO2020261156A1 (en) 2020-12-30
CN114026073A (zh) 2022-02-08
AU2020302352A1 (en) 2022-01-20
EP3990437A1 (en) 2022-05-04
AU2020302352B2 (en) 2023-03-23
IL288214A (en) 2022-01-01
KR20220011712A (ko) 2022-01-28
MA56387A (fr) 2022-05-04
TW202114996A (zh) 2021-04-16
ECSP21093541A (es) 2022-01-31
TWI817018B (zh) 2023-10-01
US11414404B2 (en) 2022-08-16
JP7169469B2 (ja) 2022-11-10

Similar Documents

Publication Publication Date Title
CU20210098A7 (es) Derivados de quinazolin-4-one útiles para el tratamiento de enfermedades y trastornos asociados con braf
CO2019008783A2 (es) Compuestos dinucleotidos ciclicos para el tratamiento del cancer
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CY1124476T1 (el) Egfr αναστολεας, και παρασκευη και εφαρμογη αυτου
EA201990187A1 (ru) Антипролиферационные средства на основе пиримидина
NI201700174A (es) Derivados de amidas policíclicas como inhibidores de cdk
EA201891879A1 (ru) Иммуномодуляторы
CL2020000375A1 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre.
EA201991622A1 (ru) Комплексная терапия для лечения рака
GEP20186933B (en) Substituted dihydroisoquinoline compounds
PH12021550296A1 (en) Substituted indoles and methods of use thereof
CR20220626A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
CY1121885T1 (el) Αντι-ογκικες ενωσεις
EA202191519A1 (ru) Модуляторы trex1
CL2022000093A1 (es) Imidazopirimidinas como inhibidores de eed y uso de estas
PH12018502473A1 (en) Pegylated carfilzomib compounds
MX2019009356A (es) Sulfinilpiridinas y su uso en el tratamiento del cancer.
CL2021000296A1 (es) Inhibidores tipo indol y azaindol de enzimas pad.
CL2020001589A1 (es) Proceso para la preparación de derivados de quinolina.
BR112019003130A2 (pt) agonista de ppargama para tratamento de cânceres de sangue
CO2020010306A2 (es) Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado.
MX2020003921A (es) Proceso para producir compuestos de tipo piridazinona herbicidas.
CO2021014351A2 (es) Derivados de quinolina y su uso para el tratamiento del cáncer
MX2018001575A (es) Compuestos triciclicos y su uso en el tratamiento del cancer.